Related Experiment Video
Updated: May 13, 2025

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Benzyl alcohol improves Ang II-induced vascular and renal injury
1Department of Cardiology, Affiliated Children's Hospital of Jiangnan University (Wuxi Children's Hospital), Wuxi, Jiangsu, China.
Insights
Benzyl alcohol (BA) effectively lowers blood pressure and improves vascular and kidney function in a mouse model of hypertension. This study highlights BA as a potential therapeutic agent for managing pediatric hypertension and its associated complications.
Area of Science:
- Metabolomics
- Cardiovascular Research
- Pediatric Nephrology
Background:
- Pediatric hypertension is complex, with metabolic factors contributing to its development.
- Metabolomics analysis identified Benzyl alcohol (BA) as a potential therapeutic target.
Purpose of the Study:
- To investigate the therapeutic effects of Benzyl alcohol (BA) on Angiotensin II (Ang II)-induced vascular and renal injury in mice.
- To evaluate BA's impact on blood pressure, vascular remodeling, and kidney function.
Main Methods:
- Established a vascular remodeling model in mice using Angiotensin II (Ang II) infusion.
- Utilized bioinformatics for metabolite identification.
- Assessed blood pressure, vascular structure (HE, Masson staining), and kidney pathology (HE).
- Measured serum markers of kidney function (urea nitrogen, creatinine, cystatin C).
Main Results:
- Benzyl alcohol (BA) significantly reduced systolic (11.58%) and diastolic (14.62%) blood pressure.
- BA treatment restored impaired vasodilation reactivity.
- BA attenuated Ang II-induced vascular thickening, collagen deposition, and renal structural damage.
- BA reversed elevated serum urea nitrogen, creatinine, and cystatin C levels.
Conclusions:
- Benzyl alcohol (BA) demonstrates significant potential in ameliorating Angiotensin II (Ang II)-induced hypertension.
- BA improves vasodilatory response, reduces vascular remodeling, and protects against renal injury.
- BA represents a promising therapeutic candidate for pediatric hypertension management.
Background/Aim:
The etiology of hypertension in pediatric populations is complex and multifactorial, with metabolic abnormalities playing a fundamental role in the pathogenesis of the condition. This study investigates the therapeutic effects of Benzyl alcohol (BA), identified through metabolomics analysis of pediatric hypertension serum, on Angiotensin II (Ang II)-induced vascular and renal injury in murine models.
Materials And Methods:
Male C57BL/6 mice were used to establish a vascular remodeling model by continuous 4-week Ang II infusion using a subcutaneous osmotic pump. Bioinformatics was used to identify target metabolites. The tail artery, common carotid artery diastolic, and systolic pressures in mice were determined with a blood pressure monitor. Vascular structure changes were assessed with HE and Masson staining, while kidney pathology was examined using HE. Serum urea nitrogen, creatinine, and cystatin C levels were measured with ELISA kit.
Results:
Metabolomics analysis identified metabolite BA as a potential target for hypertension management. Compared to the Ang II group, BA reduced systolic blood pressure by 11.58% and diastolic blood pressure by 14.62% in the fourth week. After sodium nitroprusside treatment, the Ang II group showed reduced vasodilation reactivity versus the control. BA significantly restored this reactivity, unlike acetylcholine. Furthermore, BA was observed to attenuate Ang II-induced vascular mediator thickening, the mediator-to-lumen ratio, and collagen deposition. Ang II administration resulted in renal structural damage and increased concentrations of urea nitrogen, creatinine, and serum cystatin C, which was reversed by BA treatment.
Conclusion:
BA exhibits potential in enhancing the vasodilatory response, vascular remodeling, and renal injury associated with Ang II.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Action of β1 Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers

